Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$830M |
| 2 |
UnitedHealth
UNH
|
+$769M |
| 3 |
Arthur J. Gallagher & Co
AJG
|
+$691M |
| 4 |
Amazon
AMZN
|
+$654M |
| 5 |
Bank of America
BAC
|
+$634M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.23B |
| 2 |
NVIDIA
NVDA
|
+$550M |
| 3 |
Spotify
SPOT
|
+$473M |
| 4 |
Citigroup
C
|
+$460M |
| 5 |
Boston Scientific
BSX
|
+$428M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 3.13% |
| 2 | Technology | 2.97% |
| 3 | Financials | 2.19% |
| 4 | Consumer Discretionary | 2.09% |
| 5 | Industrials | 1.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
6526
VanEck CLO ETF
CLOI
$1.53B
| $1.25M | ﹤0.01% |
+23,739
| New | +$1.26M |
|
6527
Conductor Global Equity Value ETF
CGV
$136M
| $1.25M | ﹤0.01% |
+99,609
| New | +$1.31M |
|
6528
CALL
Penske Automotive Group
PAG
$14.3B
| $1.25M | ﹤0.01% |
8,200
-32,900
| -80% | -$5.22M |
|
6529
ProShares UltraPro Russell2000
URTY
$360M
| $1.25M | ﹤0.01% |
25,375
-124,505
| -83% | -$6.96M |
|
6530
Goldman Sachs Future Tech Leaders Equity ETF
GTEK
$254M
| $1.25M | ﹤0.01% |
+38,641
| New | +$1.25M |
|
6531
YieldMax MSTR Option Income Strategy ETF
MSTY
$755M
| $1.25M | ﹤0.01% |
+9,488
| New | +$1.5M |
|
6532
PUT
VEON
VEON
$3.93B
| $1.25M | ﹤0.01% |
31,100
+17,800
| +134% | +$591K |
|
6533
American Century US Quality Growth ETF
QGRO
$2.03B
| $1.25M | ﹤0.01% |
12,505
-9,115
| -42% | -$895K |
|
6534
iShares iBonds Dec 2032 Term Corporate ETF
IBDX
$1.74B
| $1.25M | ﹤0.01% |
50,688
-35,130
| -41% | -$879K |
|
6535
PUT
Agios Pharmaceuticals
AGIO
$2.01B
| $1.25M | ﹤0.01% |
37,900
+22,800
| +151% | +$1.07M |
|
|
FEAC
6536
Fidelity Enhanced U.S. All-Cap Equity ETF
FEAC
$17.7M
| $1.24M | ﹤0.01% |
+49,998
| New | +$1.28M |
|
|
SKYT
6537
PUT
DELISTED
SkyWater Technology
SKYT
| $1.24M | ﹤0.01% |
90,100
+38,400
| +74% | +$381K |
|
6538
Wahed FTSE USA Shariah ETF
HLAL
$959M
| $1.24M | ﹤0.01% |
23,572
+9,158
| +64% | +$482K |
|
6539
Arcutis Biotherapeutics
ARQT
$3.22B
| $1.24M | ﹤0.01% |
89,168
-2,941,905
| -97% | -$32.2M |
|
6540
Hippo Holdings
HIPO
$872M
| $1.24M | ﹤0.01% |
46,349
+10,867
| +31% | +$267K |
|
|
RVNC
6541
PUT
DELISTED
Revance Therapeutics, Inc.
RVNC
| $1.24M | ﹤0.01% |
407,800
+361,200
| +775% | +$1.57M |
|
6542
CALL
Aurinia Pharmaceuticals
AUPH
$2.03B
| $1.24M | ﹤0.01% |
138,000
-3,500
| -2% | -$28.6K |
|
6543
Kennametal
KMT
$2.42B
| $1.24M | ﹤0.01% |
51,589
+17,720
| +52% | +$472K |
|
6544
PUT
Invesco CurrencyShares Australian Dollar Trust
FXA
$94.9M
| $1.24M | ﹤0.01% |
20,200
+8,000
| +66% | +$517K |
|
6545
CALL
Celldex Therapeutics
CLDX
$3.29B
| $1.24M | ﹤0.01% |
49,000
-34,900
| -42% | -$948K |
|
6546
PUT
Qiagen
QGEN
$8.8B
| $1.24M | ﹤0.01% |
27,028
+6,611
| +32% | +$296K |
|
6547
PUT
NeoGenomics
NEO
$2.08B
| $1.24M | ﹤0.01% |
75,000
+52,300
| +230% | +$812K |
|
|
BECN
6548
DELISTED
Beacon Roofing Supply, Inc.
BECN
| $1.24M | ﹤0.01% |
12,159
-86,939
| -88% | -$8.77M |
|
6549
CALL
IDEX
IEX
$17.7B
| $1.23M | ﹤0.01% |
5,900
-700
| -11% | -$153K |
|
|
HONE
6550
DELISTED
HarborOne Bancorp
HONE
| $1.23M | ﹤0.01% |
104,365
+33,290
| +47% | +$422K |
|
Similar funds
Ken Griffin's Q4 2024 Portfolio in Review
As of Q4 2024, Ken Griffin held 15,826 positions worth $578B, up 11% from $518B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Ken Griffin deployed $35.2B of net new capital in Q4 2024, opening 1,745 new positions and adding to 6,428 existing holdings. Its largest new stake was Zoetis: 1,090,499 shares worth $178M.
By sector, the portfolio is most concentrated in Healthcare at 3.1% of assets, up from 2.9% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $1.23B trimmed.
- Ken Griffin's largest Q4 2024 buy was Zoetis: 1,090,499 shares worth $178M.
- Ken Griffin added most to Boeing in Q4 2024, an estimated $830M increase.
- Ken Griffin's biggest Q4 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.23B.
- Ken Griffin fully exited Spotify in Q4 2024, selling an estimated $473M.
- Ken Griffin's ten largest holdings make up 31% of its $578B portfolio in Q4 2024.
- Ken Griffin opened 1,745 new positions and closed 1,423 in Q4 2024.
- Ken Griffin's portfolio value rose 11% quarter-over-quarter to $578B.
Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.